Public Employees Retirement System of Ohio Sells 110,283 Shares of Cellebrite DI Ltd. $CLBT

Public Employees Retirement System of Ohio decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 80.5% in the 1st quarter, Holdings Channel reports. The firm owned 26,700 shares of the company’s stock after selling 110,283 shares during the period. Public Employees Retirement System of Ohio’s holdings in Cellebrite DI were worth $368,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its stake in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Cellebrite DI in the 3rd quarter worth $40,000. CWM LLC increased its holdings in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the last quarter. First Horizon Corp raised its position in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after buying an additional 2,337 shares in the last quarter. Finally, Vestcor Inc purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at $70,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Down 0.9%

NASDAQ:CLBT opened at $15.64 on Thursday. The firm has a market capitalization of $3.90 billion, a P/E ratio of 55.86, a P/E/G ratio of 1.95 and a beta of 1.18. The company has a fifty day moving average of $14.48 and a 200 day moving average of $14.11. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98.

Insider Activity

In related news, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 158,191 shares of company stock valued at $2,479,438. Insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CLBT shares. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, DA Davidson began coverage on Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.